Nkarta, Inc. (NKTX)
NASDAQ:NKTX
Want to see NKTX full AI Analyst Report?
Top Page
Nkarta
(NASDAQ:NKTX)
Select Model
Select Model
Rating:54Neutral
Price Target:
$3.50
▲(0.86% Upside)
Action:Reiterated
Date:05/14/26
The score is constrained primarily by weak financial performance typical of a pre-revenue biotech (no revenue and continued cash burn with declining equity). This is partially offset by a relatively conservative balance sheet and favorable technical trend/momentum. Valuation remains a headwind because losses (negative P/E) limit traditional valuation signals and there is no dividend support.
Positive Factors
Allogeneic off-the-shelf NK cell platform
Nkarta's focus on allogeneic, off-the-shelf NK cell therapies is a durable strategic advantage versus autologous approaches. Scalable manufacturing and off-the-shelf delivery can reduce per-patient complexity, support broader commercial rollouts, and address larger patient populations once clinical proof and approvals are achieved.
Negative Factors
Pre-commercial with no product revenue
Nkarta is a pre-revenue biotech with no product sales, leaving the company dependent on collaborations and financings to fund operations. Until product approvals and commercialization occur, revenue visibility is limited and the business model lacks recurring commercial cash flows to offset R&D spend.
Read all positive and negative factors
Positive Factors
Negative Factors
Allogeneic off-the-shelf NK cell platform
Nkarta's focus on allogeneic, off-the-shelf NK cell therapies is a durable strategic advantage versus autologous approaches. Scalable manufacturing and off-the-shelf delivery can reduce per-patient complexity, support broader commercial rollouts, and address larger patient populations once clinical proof and approvals are achieved.
Read all positive factors
Nkarta (NKTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$236.10M
Dividend YieldN/A
Average Volume (3M)983.43K
Price to Earnings (P/E)―
Beta (1Y)1.55
Revenue GrowthN/A
EPS Growth10.70%
CountryUS
Employees157
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.34
Shares Outstanding71,545,360
10 Day Avg. Volume644,627
30 Day Avg. Volume983,433
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-121.26
Enterprise Value/Ebitda-2.80
Forecast
1Y Price Target
$11.80Price Target Upside240.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.45
Revenue Forecast (FY)N/A
Nkarta Business Overview & Revenue Model
Company Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (...
How the Company Makes Money
Nkarta does not have product sales and, as a clinical-stage biotech, has historically generated little to no recurring revenue from commercial operations. Its earnings, when present, have primarily come from collaboration-related arrangements typi...
Nkarta Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.34M | -9.19M | 0.00 | -5.87M | 0.00 | 0.00 |
| EBITDA | -101.50M | -112.01M | -119.04M | -120.48M | -116.32M | -84.67M |
| Net Income | -99.93M | -104.08M | -108.79M | -117.50M | -113.84M | -86.08M |
Balance Sheet | ||||||
| Total Assets | 372.07M | 404.21M | 501.20M | 378.88M | 472.94M | 273.90M |
| Cash, Cash Equivalents and Short-Term Investments | 230.43M | 276.28M | 267.35M | 248.19M | 352.14M | 238.09M |
| Total Debt | 75.00M | 76.42M | 80.27M | 88.34M | 82.93M | 12.46M |
| Total Liabilities | 86.21M | 91.88M | 93.23M | 105.60M | 100.73M | 22.94M |
| Stockholders Equity | 285.86M | 312.32M | 407.98M | 273.29M | 372.21M | 250.97M |
Cash Flow | ||||||
| Free Cash Flow | -88.39M | -89.91M | -104.11M | -114.31M | -104.11M | -72.95M |
| Operating Cash Flow | -87.29M | -88.70M | -99.70M | -86.16M | -57.00M | -67.93M |
| Investing Cash Flow | 61.90M | 100.32M | -129.56M | 79.02M | -184.69M | 32.53M |
| Financing Cash Flow | 147.00K | 141.00K | 226.08M | 691.00K | 219.01M | 1.20M |
Nkarta Technical Analysis
Positive
3.47
Price Trends
2.71
Positive
2.49
Positive
2.27
Positive
Market Momentum
0.10
Negative
60.61
Neutral
87.62
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NKTX, the sentiment is Positive. The current price of 3.47 is above the 20-day moving average (MA) of 3.03, above the 50-day MA of 2.71, and above the 200-day MA of 2.27, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 60.61 is Neutral, neither overbought nor oversold. The STOCH value of 87.62 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NKTX.
Nkarta Risk Analysis
Nkarta disclosed 80 risk factors in its most recent earnings report. Nkarta reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nkarta Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $262.86M | 7.13 | 47.72% | ― | 163.35% | ― | |
54 Neutral | $236.10M | -2.42 | -30.90% | ― | ― | 10.70% | |
54 Neutral | $404.68M | -5.31 | -50.68% | ― | -12.37% | 19.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $457.78M | -13.39 | -60.73% | ― | -78.29% | 54.16% | |
49 Neutral | $270.30M | -8.41 | -147.78% | ― | ― | -16.88% | |
44 Neutral | $33.67M | -1.29 | 241.39% | ― | ― | 38.95% |
* Healthcare Sector Average
NKTX
Nkarta
3.25
1.51
86.78%
CGEN
Compugen
2.63
1.16
78.91%
CCCC
C4 Therapeutics
4.37
3.12
249.60%
STTK
Shattuck Labs
5.95
4.94
489.11%
TVGN
Tevogen Bio Holdings
7.91
-56.59
-87.74%
NVCT
Nuvectis Pharma
9.75
0.34
3.61%
Nkarta Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Nkarta Launches $100 Million At-the-Market Stock Offering
Neutral
Mar 26, 2026
On March 25, 2026, Nkarta, Inc. entered into a Sales Agreement with Stifel, Nicolaus Company for an at-the-market equity offering of up to $100 million of its common stock, with Stifel acting as sales agent and earning a commission of up to 3% on...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.